Pfizer (PFE) EBT (2009 - 2026)

Pfizer has disclosed EBT across 18 years of filings, most recently posting $3.2 billion for Q1 2026.

• In Q1 2026, EBT rose 13.82% year-over-year to $3.2 billion; the TTM figure through Mar 2026 stood at $7.9 billion (down 26.92% YoY), while the FY2025 annual figure was $7.5 billion, down 6.27% from the prior year.
• EBT grew to $3.2 billion in Q1 2026, from -$1.6 billion in the prior quarter.
• Over the last five years, EBT for PFE reached as high as $11.4 billion in Q3 2022 and fell as low as -$4.1 billion in Q4 2023.
• The 5-year median for EBT is $3.2 billion (2026), against an average of $3.3 billion.
• Annual changes were most pronounced in 2023 — EBT sank 137.24% — and 2025, when it soared 3055.34%.
• A 5-year view of EBT shows it stood at $9.0 billion in 2022, then slumped by 145.87% to -$4.1 billion in 2023, then jumped by 214.19% to $4.7 billion in 2024, then slumped by 134.83% to -$1.6 billion in 2025, then soared by 293.06% to $3.2 billion in 2026.
• According to Business Quant data, EBT over the past three periods registered $3.2 billion, -$1.6 billion, and $3.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.